[go: up one dir, main page]

PE20030885A1 - Suspension oral de sabor agradable y metodo - Google Patents

Suspension oral de sabor agradable y metodo

Info

Publication number
PE20030885A1
PE20030885A1 PE2003000249A PE2003000249A PE20030885A1 PE 20030885 A1 PE20030885 A1 PE 20030885A1 PE 2003000249 A PE2003000249 A PE 2003000249A PE 2003000249 A PE2003000249 A PE 2003000249A PE 20030885 A1 PE20030885 A1 PE 20030885A1
Authority
PE
Peru
Prior art keywords
drug
water
bitter flavor
dihydro
particles
Prior art date
Application number
PE2003000249A
Other languages
English (en)
Inventor
Ismat Ullah
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20030885A1 publication Critical patent/PE20030885A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION EN FORMA DE UN POLVO SECO, QUE COMPRENDE I)PARTICULAS DE UN FARMACO DE FORMULA (I), QUE ES MONOHIDRATO DE METANSULFONATO DEL ACIDO 1-CICLOPROPIL-8-(DIFLUOROMETOXI)-7-[(1R)-1-METIL-2,3-DIHIDRO-1H-5-ISOINDOLIL]-4-OXO-1,4-DIHIDRO-3-QUINOLINCARBOXILICO (DESQUINOLONA), EL CUAL CUANDO SE SOLUBILIZA TIENE UN SABOR AMARGO, ES ASI QUE DICHAS PARTICULAS SE TRATAN DE MANERA QUE CON LA ADICION DE AGUA A ELLAS, ESTAS SE HACEN MENOS SOLUBLES O FORMAN UN PRECIPITADO IN SITU SUSPENDIDO EN EL AGUA QUE ESTA ESENCIALMENTE LIBRE DEL SABOR AMARGO, DE MANERA QUE EL FARMACO SE LIBERA DEL SABOR AMARGO SIN EL USO O NECESIDAD DE UN POLIMERO O RECUBRIMIENTO EN CERA O MICROENCAPSULACION; II)UNO O MAS AGENTES MODIFICADORES DE pH PARA EFECTUAR LA REDUCCION EN SOLUBILIDAD DEL FARMACO O LA PRECIPITACION DEL MISMO, QUE PUEDE SER ALCALINO DE MODO QUE PROPORCIONA UN pH DE LA SUSPENSION SUPERIOR AL pH DEL FARMACO EN AGUA O PUEDE SER ACIDIFICANTE Y PROPORCIONA UN pH DE LA SUSPENSION INFERIOR AL pH DEL FARMACO EN AGUA
PE2003000249A 2002-03-12 2003-03-12 Suspension oral de sabor agradable y metodo PE20030885A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36370402P 2002-03-12 2002-03-12

Publications (1)

Publication Number Publication Date
PE20030885A1 true PE20030885A1 (es) 2003-10-23

Family

ID=28041802

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000249A PE20030885A1 (es) 2002-03-12 2003-03-12 Suspension oral de sabor agradable y metodo

Country Status (16)

Country Link
US (1) US7175856B2 (es)
EP (1) EP1482789A4 (es)
JP (1) JP4619658B2 (es)
CN (1) CN100337630C (es)
AR (1) AR038947A1 (es)
AU (1) AU2003220058B2 (es)
BR (1) BR0308343A (es)
CA (1) CA2478411C (es)
MX (1) MXPA04008720A (es)
NO (1) NO20043986L (es)
NZ (1) NZ534746A (es)
PE (1) PE20030885A1 (es)
PL (1) PL212421B1 (es)
TW (1) TW200304832A (es)
WO (1) WO2003077842A2 (es)
ZA (1) ZA200406585B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005023193D1 (de) * 2004-10-15 2010-10-07 Suedzucker Ag Verbessertes trommelcoating-verfahren
US8653145B2 (en) * 2005-09-22 2014-02-18 Eaton Scientific Systems, Ltd. Method for alleviating climacteric symptoms
CN102964296B (zh) 2007-03-28 2015-03-25 阿普泰克斯科技公司 去铁酮的氟化衍生物
US20100210604A1 (en) 2007-06-13 2010-08-19 Meythaler Jay M Zwitterion solution for low-volume therapeutic delivery
US20110021469A1 (en) * 2007-06-13 2011-01-27 Meythaler Jay M baclofen solution for low-volume therapeutic delivery
JP5009707B2 (ja) * 2007-07-10 2012-08-22 東和薬品株式会社 不快な味がマスキングされたキノロン系抗菌剤の経口投与用液剤
US7884227B2 (en) * 2007-10-26 2011-02-08 Navinta Llc Felbamate with improved bulk density
GB2470494B (en) * 2008-01-17 2012-08-08 Univ Holy Ghost Duquesne Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS
CN102014904B (zh) * 2008-04-25 2013-02-06 阿普泰克斯科技公司 具有适口味道的去铁酮液体配制品
ES2351643B1 (es) * 2009-07-27 2011-09-15 Laboratorio Jaer,S.A. Utilización de xilitol o sus derivados para el enmascaramiento gustativo de quimioterápicos del grupo del ácido quinolon-o-naftiridoncarboxílico administrados en alimentos destinados a ganado porcino.
EP2343089A4 (en) 2008-09-23 2013-05-01 Jaer S A Lab USE OF XYLITOL OR DERIVATIVES THEREOF FOR MASKING THE TASTE OF CHEMOTHERAPEUTIC MEDICAMENTS OF THE CHINOLO-N-NAPHTHYRIDONE-CARBOXYLIC ACID GROUP FOR PIG DICULTINATION
ES2335334B1 (es) * 2008-09-23 2011-02-09 Laboratorio Jaer, S.A. Utilizacion del xilitol para el enmascaramiento gustativo de amargantes en alimentos para animales.
WO2011000104A1 (en) 2009-07-03 2011-01-06 Apotex Technologies Inc. Fluorinated derivatives of 3-hydroxypyridin-4-ones
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
US20110236494A1 (en) * 2010-03-04 2011-09-29 Ranbaxy Laboratories Limited Ciprofloxacin oral suspension
GB201006218D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
CN102397546A (zh) * 2010-09-10 2012-04-04 广州自远生物科技有限公司 一种用于嗅觉或味觉敏感型动物的药物给药方法
CN102397552B (zh) * 2010-09-10 2016-06-08 广州自远生物科技有限公司 一种含喹诺酮类的药物复合制剂及其制备方法和应用
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
LT3524595T (lt) 2014-08-28 2022-09-26 Eisai R&D Management Co., Ltd. Aukšto grynumo chinolino darinys ir jo gamybos būdas
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
US11648202B2 (en) * 2017-10-13 2023-05-16 Research Triangle Institute Hydroxychloroquine sulfate formulations and methods for preparation and use thereof
CN110151704A (zh) * 2019-07-05 2019-08-23 华裕(无锡)制药有限公司 阿奇霉素干混悬剂的制备方法
WO2025043236A1 (en) * 2023-08-24 2025-02-27 Joseph Fuisz Edible oral films, compositions, method of manufacture and packaging systems

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8103843L (sv) 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine
JPS61180771A (ja) * 1985-01-05 1986-08-13 バイエル・アクチエンゲゼルシヤフト 安定な抗バクテリア剤水溶液
GB8623557D0 (en) * 1986-10-01 1986-11-05 Boots Co Plc Therapeutic agents
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
DE3719764A1 (de) * 1987-06-13 1988-12-22 Bayer Ag Ionenaustauscherharze beladen mit chinoloncarbonsaeurederivaten, ihre herstellung und verwendung
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
DE3831514A1 (de) * 1988-09-16 1990-03-22 Bayer Ag Ph-neutrale waessrige loesungen von chinoloncarbonsaeuren
US4975465A (en) * 1989-03-28 1990-12-04 American Home Products Corporation Orally administrable ibuprofen compositions
US5262179A (en) * 1989-09-13 1993-11-16 Nicholas Kiwi Pty Ltd. Non-effervescent ibuprofen compositions
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
IT1246383B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
JP3184239B2 (ja) * 1991-04-25 2001-07-09 京都薬品工業株式会社 矯味経口用医薬組成物
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
JPH05309314A (ja) 1992-05-07 1993-11-22 Sumitomo Pharmaceut Co Ltd コーティング方法
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
NZ290946A (en) * 1994-08-12 1997-12-19 Toyama Chemical Co Ltd Quinolone- or naphthyridone-carboxylic acid derivatives
AU689663B2 (en) * 1994-10-14 1998-04-02 Janssen Pharmaceutica N.V. Sabeluzole oral suspensions
GB9421837D0 (en) * 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
ZA961018B (en) * 1995-02-08 1997-08-08 Yamanouchi Europ Bv Oral dosage-forms containing a beta-lactam antibiotic.
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
CN1100053C (zh) * 1996-02-09 2003-01-29 富山化学工业株式会社 喹诺酮羧酸衍生物或它们的盐类
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
JP3424038B2 (ja) * 1996-06-17 2003-07-07 株式会社日本点眼薬研究所 合成抗菌剤水性組成物
AP1409A (en) * 1999-05-27 2005-06-13 Pfizer Prod Inc Ziprasidone suspension.
US6239141B1 (en) * 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions

Also Published As

Publication number Publication date
TW200304832A (en) 2003-10-16
US7175856B2 (en) 2007-02-13
ZA200406585B (en) 2005-11-30
CN1642415A (zh) 2005-07-20
CN100337630C (zh) 2007-09-19
NO20043986L (no) 2004-09-23
BR0308343A (pt) 2006-06-06
CA2478411C (en) 2010-09-28
WO2003077842A3 (en) 2004-03-25
MXPA04008720A (es) 2004-12-06
US20030187019A1 (en) 2003-10-02
WO2003077842A2 (en) 2003-09-25
NZ534746A (en) 2006-06-30
EP1482789A4 (en) 2010-12-29
AR038947A1 (es) 2005-02-02
EP1482789A2 (en) 2004-12-08
JP4619658B2 (ja) 2011-01-26
CA2478411A1 (en) 2003-09-25
JP2006504620A (ja) 2006-02-09
PL212421B1 (pl) 2012-09-28
AU2003220058B2 (en) 2008-05-01
AU2003220058A1 (en) 2003-09-29
PL373570A1 (en) 2005-09-05

Similar Documents

Publication Publication Date Title
PE20030885A1 (es) Suspension oral de sabor agradable y metodo
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
DE60234618D1 (de) Stabile zusammensetzung enhaltend partikel in einer gefrorenen wässrigen matrix
BR0309142A (pt) Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas que permitem a liberação modificada de princìpio(s) ativo(s)
DE69934505D1 (de) Im munde zerfallende tablette enthaltend ein benzimidazole
AP1817A (en) Stabilized oral suspension formulation.
ATE464049T1 (de) Pharmazeutische kombinationen von hydrocodon und naltrexon
BR0309093A (pt) Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas permitindo a liberação modificada de amoxicilina
PT1587514E (pt) Composicao farmaceutica de accao rapida
DK1210068T3 (da) Anvendelse af simple aminosyrer til dannelse af poröse partikler
IL165591A0 (en) Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents pharmaceutical compositions including the same and methods fortheir use
ATE340796T1 (de) Dihydropyrrolo(1,2-aöindol- und tetrahydropyrido)1,2-aöindolderivate als prostaglandin rezeptor antagonisten
AU2002322478A1 (en) Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
MXPA03011908A (es) Derivados de tetrahidroquinolina.
DE50011218D1 (de) Verwendung von nanoskaligen sterolen und sterolestern
ATE427983T1 (de) Bariumsulfat, verfahren zu dessen herstellung und dessen verwendung
MXPA02011561A (es) Composicion farmaceutica.
TW200624119A (en) An oral liquid pharmaceutical composition of leukotriene antagonists
FR2876383B1 (fr) Composition de revetement anti-reflechissant superieur et procede de formation de motif de dispositif semiconducteur l'utilisant
WO2007146943A3 (en) Nanoparticulate kinase inhibitor formulations
WO2006135689A3 (en) Nanoparticulate ebastine formulations
NO20045456L (no) Fischer-Tropsch-katalysator fremstilt med et preforstadium av hoy renhet
JP2007500181A5 (es)
NO20013851D0 (no) Salter med opprettholdt frigivning av farmasoytisk ative peptider samt fremstilling derav
WO2004110441A8 (en) Pharmaceutical formulations comprising amoxicillin and clavulanate

Legal Events

Date Code Title Description
FD Application declared void or lapsed